永和智控(002795.SZ)：擬收購西安醫科腫瘤醫院37.2139%股權
格隆匯12月19日丨永和智控(002795.SZ)公佈，公司全資子公司成都永和成醫療科技有限公司(“成都永和成”)擬以支付現金方式收購西安醫科腫瘤醫院有限公司(“西安醫科”)37.2139%股權(“標的資產”、“交易標的”)。此次交易完成後，成都永和成將合計持有西安醫科57%的股權，西安醫科成為成都永和成的控股子公司。
經西安醫科股東會決定，同意龍巖市長峯網絡科技合夥企業(有限合夥)(“龍巖長峯”)將其所持西安醫科37.2139%股權轉讓給成都永和成。
公吿顯示，西安醫科腫瘤醫院位於西安市二環南路西段60號永安大廈，是一家專注精準放射治療的全國連鎖腫瘤專科醫院。醫院設置牀位100張，診療科目包括內科(腫瘤內科)、外科(腫瘤外科)、放射治療科、醫學檢驗科、醫學影像科、中醫(門診)等。目前已配備瓦里安直線加速器(速鋭)、Infini頭部伽瑪刀、體部伽瑪刀、CT模擬定位機、西門子PET-CT、西門子3.0T核磁成像系統、西門子128層螺旋CT、腫瘤射頻熱療機等高端先進的醫療設備，可廣泛應用於全身各部位腫瘤的診治。
為拓展上市公司業務範圍，增強持續盈利能力和綜合實力，公司實施了向醫療健康產業的戰略轉型，本次收購的西安醫科將作為公司醫療戰略拓展的重要補充。企業價值主要體現在核心競爭力上，醫院作為一個特殊的行業，核心競爭力是醫院在其長期的醫療實踐及經營活動中逐步積累的。西安醫科系公司的參股公司，目前尚未盈利，但從腫瘤精準放射治療的發展趨勢、地區醫療資源的整體需求、西安醫科的精準服務定位以及已具備的人才和設備優勢等綜合考量，西安醫科已具備一定的發展潛力和優勢。因此，公司經審慎決策實施本次收購事項，系公司醫療產業長期戰略佈局的延續，有利於進一步完善公司在醫療行業的佈局，有利於公司可持續發展，符合公司整體的業務發展規劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
